Millman, Jeffrey R.Xie, ChunhuiVan Dervort, AlanaGürtler, MadsPagliuca, Felicia W.Melton, Douglas2016-06-142016Millman, Jeffrey R., Chunhui Xie, Alana Van Dervort, Mads Gürtler, Felicia W. Pagliuca, and Douglas A. Melton. 2016. “Generation of stem cell-derived β-cells from patients with type 1 diabetes.” Nature Communications 7 (1): 11463. doi:10.1038/ncomms11463. http://dx.doi.org/10.1038/ncomms11463.2041-1723http://nrs.harvard.edu/urn-3:HUL.InstRepos:27320369We recently reported the scalable in vitro production of functional stem cell-derived β-cells (SC-β cells). Here we extend this approach to generate the first SC-β cells from type 1 diabetic patients (T1D). β-cells are destroyed during T1D disease progression, making it difficult to extensively study them in the past. These T1D SC-β cells express β-cell markers, respond to glucose both in vitro and in vivo, prevent alloxan-induced diabetes in mice and respond to anti-diabetic drugs. Furthermore, we use an in vitro disease model to demonstrate the cells respond to different forms of β-cell stress. Using these assays, we find no major differences in T1D SC-β cells compared with SC-β cells derived from non-diabetic patients. These results show that T1D SC-β cells could potentially be used for the treatment of diabetes, drug screening and the study of β-cell biology.en-USJournal Article2016-06-1410.1038/ncomms11463